Rushworth, Linda K.
Hewit, Kay
Munnings-Tomes, Sophie
Somani, Sukrut
James, Daniel
Shanks, Emma
Dufès, Christine
Straube, Anne
Patel, Rachana
Leung, Hing Y.
Funding for this research was provided by:
Prostate Cancer Foundation (2016, 2016, 2016)
Dunhill Medical Trust (R463/0216, R463/0216)
Worldwide Cancer Research (16-1303, 16-1303)
Lister Institute of Preventive Medicine (200870/Z/16/Z)
Cancer Research UK (C596/A17196, CRUK A15151)
Article History
Received: 30 May 2019
Revised: 5 November 2019
Accepted: 19 November 2019
First Online: 17 December 2019
Ethics approval and consent to participate
: In vivo experiments were approved by the local ethics committee (the University of Strathclyde Animal Welfare and Ethical Review Body), complied with the ARRIVE guidelines and were carried out in accordance with the UK Home Office regulations (UK Animals (Scientific Procedures) Act 1986) under Project Licence P32E328B7.
: Not applicable.
: Supplementary methods and figures can be found on the <i>British Journal of Cancer’s</i> website. Full details of the drug-repurposing data set produced and analysed during this study are available from the corresponding author on reasonable request.
: The authors declare no competing interests.
: This work was supported by the Prostate Cancer Foundation Challenge Award (R.P. and H.Y.L.), Cancer Research UK Beatson Institute (C596/A17196 and CRUK A15151; H.Y.L.), Lister Institute of Preventive Medicine and Wellcome Trust Investigator Award (200870/Z/16/Z; A.S.), Worldwide Cancer Research (16-1303; C.D. and H.Y.L.) and The Dunhill Medical Trust (R463/0216; C.D. and S.S.).